InVivoMAb Anti-SARS-CoV-2 RBD (JN.1 variant) Neutralizing Antibody (Iv0221) (VK565110)

Name: InVivoMAb Anti-SARS-CoV-2 RBD (JN.1 variant) Neutralizing Antibody (Iv0221)
Brand: abinScience
SKU: VK565110
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	VK565110
Descripción	InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing Antibody (Iv0221) [Iv0221] (VK565110) is a human monoclonal antibody detecting Spike glycoprotein in ELISA, Neutralization.
Reactividad de especies	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Aplicaciones	ELISA, Neutralization
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1, kappa
ID de clon	Iv0221
Objetivo	Spike glycoprotein, Spike, S glycoprotein, RBD
Nivel de endotoxinas	< 1 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Productos asociados	pH 7.4 Dilution Buffer
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P0DTC2
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fondo	Spike glycoprotein (RBD (Omicron/JN.1)) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors. 1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651 2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444 3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086 4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887 5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877 6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306 7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715 8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763 9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294 10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
Nota	For research use only. Not suitable for clinical or therapeutic use.

Imágenes

SDS-PAGE

SDS-PAGE for InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing Antibody (Iv0221).
Bioactivity

Detects SARS-CoV-2 RBD(JN.1) in indirect ELISAs.
Bioactivity

Detects Recombinant SARS-CoV-2 RBD (JN.1) Protein, C-His (Cat No.: VK565421) in indirect ELISA.